ArticleInfection and drug resistance2026
Comparative Effectiveness of Colistin Sodium versus Polymyxin B Sulfate Against CR-GNB: A Retrospective Cohort Study.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the clinical effectiveness of colistin sodium (CS) and polymyxin B sulfate (PMB) in the treatment of carbapenem-resistant Gram-negative bacteria (CR-GNB) infections. Patients and methods: Adult patients receiving intravenous CS or PMB ≥ 72 hours between October 2021 and November 2022 were retrospectively enrolled. Demographic information and pertinent clinical laboratory data were collected for each patient. The primary outcome was 28-day all-cause mortality, and the secondary outcomes consisted of microbial clearance, clinical success, and normalization of inflammatory marker. Inverse probability of treatment weighting (IPTW) was applied to address potential confounding. Cox regression with IPTW was used to evaluate the association between polymyxin type and mortality. Results: A total of 93 CS patients and 118 PMB patients were included in this study. After IPTW, a significant difference in 28-day all-cause mortality was observed between the CS and PMB groups (11.0% vs 26.7%, Conclusion: Although IPTW-adjusted analysis revealed a significant difference in mortality between CS and PMB groups, multivariable Cox regression incorporating additional covariates did not confirm an independent protective effect of CS. This suggests that the observed survival benefit may be attributable to confounding, and the finding warrants validation in larger prospective multicenter studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.